Abraxane Combination Improves Survival In Treatment-Naïve Metastatic Disease
Avastin Increases Overall Survival 3.7 Months
First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma
Phase III Trial of ThermoDox Fails to Meet Primary Endpoint
Neulasta Reduces Incidence Of Febrile Neutropenia
Tivozanib Does Not Improve OS Compared to Sorafenib
In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up
Genomic Test More Accurate In Predicting Metastasis Than PSA, Tumor Stage & Grade
Protein May Link Obesity To Cancer Aggressiveness
“Triple-Negative” Should Be Split Into Subtypes, Say Researchers
NCI CTEP Approved Trials For the Month of February
Avastin Combination Approved For Metastatic Colorectal Cancer
FDA Grants Priority Review To Two Drugs in NSCLC
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
